Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631506 | 0.80 | KMT2A (0.48) | CYP2C9ALDH1A1TSHRCA1CA2 | |
| SCHEMBL8567044 | 0.73 | L3MBTL1 (0.42) | HTR6CYP2C9ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL8211984 | 0.70 | TSHR (0.41) | HTR2ACYP2C9ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL15751145 | 0.69 | ALDH1A1 (0.54) | HTR2AALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL27782679 | 0.63 | HTR6 (0.44) | HTR6HTR2ACYP2C9ALDH1A1TSHR | |
| SCHEMBL27466676 | 0.63 | CTSB (0.52) | HTR6HTR2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL31474870 | 0.61 | MAOA (0.45) | HTR6CYP2C9ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL2048495 | 0.61 | HTR2A (0.59) | HTR6HTR2AALDH1A1TSHRHSD17B10 | |
| SCHEMBL5549323 | 0.61 | EPHX1 (0.42) | HTR6CYP2C9ALDH1A1TSHRHSD17B10 | |
| SCHEMBL19020647 | 0.60 | L3MBTL1 (0.53) | HTR6CYP2C9ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115147-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| EP-2792678-A1 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20120277186-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2516446-A2 | SUBSTITUTED HEXAHYDROCHROMENO[3,4-B]PYRROLES WITH AFFINITY FOR THE SEROTONIN RECEPTOR (5-HT) FAMILY | Cephalon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2011087713-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-1638932-A1 | NOVEL PIPERAZINYL-ARYLOXY AND PIPERAZINYL-HETEROARYLOXY-N-ARYL LACTAMS | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004110994-A1 | NOVEL PIPERAZINYL-ARYLOXY AND PIPERAZINYL-HETEROARYLOXY-N-ARYL LACTAMS | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6265434-B1 | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-1996034862-A1 | TOTAL SYNTHESIS OF TAXOL AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1995012567-A1 | TOTAL SYNTHESIS OF TAXOL AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-05-11 | — | — | WO | disclosed |
| WO-1993020036-A1 | TOTAL SYNTHESIS OF TAXOL | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277186-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP11B2, CYP11B1, CYP4A11 | HTR6 874/4885HTR2A 1068/4885CYP2C9 40/4885 |
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | GPR119, INSR, OAT | HTR6 874/4885HTR2A 406/4885CYP2C9 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.